Ion Beam Applications S.A. (IOBCF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Ion Beam Applications S.A. (IOBCF) Healthcare & Pipeline Overview

Ion Beam Applications S.A. is a Belgian-headquartered medical device company specializing in advanced cancer treatment solutions, including proton therapy systems, industrial particle accelerators, and precision dosimetry. With a global presence, the company focuses on enhancing radiation therapy efficacy and safety through innovative technology and strategic R&D partnerships.

What Is the Investment Thesis for IOBCF?

Ion Beam Applications S.A. (IOBCF) is positioned within the growing advanced cancer treatment market, driven by increasing demand for precise and less invasive therapies like proton therapy. The company's dual focus on proton therapy systems and critical dosimetry solutions provides a diversified revenue stream within the medical device sector. With a market capitalization of $545M, IOBCF demonstrates a commitment to innovation through strategic R&D partnerships, such as those for Actinium-225 production and ConformalFLASH research, which could unlock future growth avenues in targeted radionuclide therapy and ultra-high dose rate radiation. The company's gross margin of 32.2% indicates solid operational efficiency in its specialized manufacturing. While its P/E ratio of 39.63 and profit margin of 2.0% suggest a growth-oriented valuation and current reinvestment, the dividend yield of 1.42% offers some return to shareholders. The company's established global presence and comprehensive service offerings for its complex medical devices underpin its competitive standing, making its continued technological advancements and market penetration key value drivers.

Based on FMP financials and quantitative analysis

IOBCF Key Highlights

Market capitalization stands at $0.50 billion, reflecting its valuation in the specialized medical device sector.

• The company maintains a gross margin of 32.2%, indicating efficient cost management relative to its revenue from complex medical systems.
• Ion Beam Applications S.A. reported a profit margin of 2.0%, demonstrating profitability within its operational framework.
• A P/E ratio of 39.63 suggests investor expectations for future growth, common for companies in innovative healthcare technology.
• The company offers a dividend yield of 1.42%, providing a return to shareholders while investing in R&D and growth initiatives.

Who Are IOBCF's Competitors?

IOBCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IOBCF's Key Strengths?

Leading position in advanced proton therapy systems and comprehensive dosimetry solutions.

• Global operational presence with established sales and service networks.
• Strategic R&D partnerships for cutting-edge cancer treatment technologies like Actinium-225 and ConformalFLASH.
• Diversified product portfolio including medical, industrial, and diagnostic accelerator technologies.
• Strong gross margin of 32.2% indicating efficient manufacturing of specialized equipment.

What Are IOBCF's Weaknesses?

Relatively low profit margin of 2.0% for a high-tech medical device company.

• High capital intensity associated with manufacturing and installing complex particle accelerators.
• Reliance on successful outcomes of long-term R&D partnerships for future growth drivers.
• Exposure to regulatory hurdles and lengthy approval processes common in the medical device industry.
• High P/E ratio of 39.63 suggesting high growth expectations that must be met.

What Could Drive IOBCF Stock Higher?

IOBCF catalyst: Further advancements and positive clinical data emerging from the strategic research and development partnership with SCK CEN for Actinium-225 (225Ac) production, potentially leading to commercialization milestones for novel targeted alpha therapies.

• Key research findings or progress reports from the agreement with the University of Pennsylvania regarding ConformalFLASH technology, which could validate its potential to revolutionize radiation delivery and attract further investment or partnerships.
• Continued global expansion of proton therapy centers and new system installations, driving revenue growth from both equipment sales and long-term service contracts.
• Increased adoption of Ion Beam Applications S.A.'s dosimetry solutions as radiation therapy techniques become more complex, necessitating enhanced precision and quality assurance.
• Potential new contracts or partnerships for its industrial accelerators, expanding its market reach beyond medical applications.

What Are the Key Risks for IOBCF?

Significant capital expenditure requirements for R&D and manufacturing of complex medical devices, which could strain financial resources if market adoption or project timelines are delayed.

• Intense competition within the advanced cancer treatment and medical device sectors, potentially leading to pricing pressures or market share erosion.
• Regulatory hurdles and lengthy approval processes for new medical devices and therapies, which could delay market entry and revenue generation from innovative products.
• The success of strategic R&D partnerships, particularly for novel radioisotopes and advanced radiation techniques, is subject to scientific and clinical uncertainties, with no guarantee of commercial viability.
• Fluctuations in healthcare spending and investment in capital-intensive medical equipment by hospitals and clinics, influenced by economic conditions and government policies.

What Are the Growth Opportunities for IOBCF?

• Growth opportunity 1: The global proton therapy market is experiencing significant expansion due to increasing cancer incidence and growing awareness of proton therapy's benefits, such as reduced side effects compared to traditional radiation. Ion Beam Applications S.A., as a leading provider of proton therapy systems and turnkey solutions, is well-positioned to capitalize on this trend. The market is projected to grow substantially over the next decade, driven by new clinic installations and technological advancements. IOBCF's established expertise and comprehensive service model provide a competitive advantage in securing new contracts and expanding its installed base globally, particularly in emerging markets where advanced cancer treatments are becoming more accessible.
• Growth opportunity 2: The demand for advanced dosimetry solutions is continuously rising as radiation therapy techniques become more complex and precise. Accurate dosimetry is critical for ensuring patient safety and treatment efficacy in oncology. Ion Beam Applications S.A.'s Dosimetry segment provides solutions that enhance efficiency and minimize errors in radiation therapy and medical imaging quality assurance. This market is driven by regulatory compliance, the need for higher precision in treatment delivery, and the increasing volume of radiation procedures. IOBCF's specialized products offer a competitive edge by addressing these critical needs, ensuring consistent revenue streams from both new installations and recurring service contracts.
• Growth opportunity 3: The strategic research and development partnership with SCK CEN for the production of Actinium-225 (225Ac) represents a significant long-term growth opportunity. 225Ac is a novel alpha-emitting radioisotope showing immense promise for targeted alpha therapy (TAT) in treating various cancers, including prostate cancer. The market for therapeutic radioisotopes is expected to grow substantially as new radiopharmaceuticals gain regulatory approval. IOBCF's involvement in enabling 225Ac production positions it at the forefront of a potentially transformative cancer treatment modality, offering a future revenue stream from the supply chain of these advanced therapies, with potential market entry within the next 5-10 years pending clinical success and regulatory clearance.
• Growth opportunity 4: The agreement with the University of Pennsylvania for advance research in ConformalFLASH presents another cutting-edge growth avenue. ConformalFLASH is an experimental ultra-high dose rate radiation delivery technique that could significantly reduce treatment times and potentially enhance therapeutic ratios by sparing healthy tissue. If successful, FLASH therapy could revolutionize radiation oncology. Ion Beam Applications S.A.'s early involvement in this research positions it to be a key technology provider should FLASH therapy become clinically viable. This strategic collaboration allows IOBCF to influence and potentially dominate a future market for next-generation radiation delivery systems, with commercialization timelines likely beyond five years.
• Growth opportunity 5: Ion Beam Applications S.A.'s line of industrial accelerators for sterilization and ionization addresses a stable and essential market. These accelerators are used in various sectors beyond healthcare, including food safety, material modification, and environmental applications. The demand for industrial sterilization and ionization services remains robust, driven by global health standards, product safety regulations, and manufacturing efficiency. IOBCF's established presence and technological expertise in this area provide a consistent revenue stream and diversification from its core medical business. The market for industrial accelerators is mature but offers steady growth, particularly with increasing global manufacturing and regulatory requirements for product safety and hygiene.

What Threats Does IOBCF Face?

• Intense competition from other medical device manufacturers in radiation oncology and diagnostics.
• Technological obsolescence if competitors develop superior or more cost-effective treatment modalities.
• Unfavorable changes in healthcare reimbursement policies or regulatory environments.
• Risks associated with the success and commercialization timelines of R&D initiatives.
• Economic downturns or geopolitical instability impacting healthcare spending and capital equipment investments.

What Are IOBCF's Competitive Advantages?

• Proprietary technology and expertise in complex particle accelerator design and manufacturing for medical and industrial applications.
• Established global installed base and reputation as a provider of advanced proton therapy systems.
• Strategic R&D partnerships with leading research institutions (SCK CEN, University of Pennsylvania) for next-generation cancer treatments.
• Comprehensive turnkey solutions and ongoing service contracts for highly specialized medical equipment, creating high switching costs.
• Strong intellectual property portfolio related to proton therapy, dosimetry, and accelerator technologies.

What Does IOBCF Do?

Ion Beam Applications S.A. (IOBCF), incorporated in 1986 and headquartered in Louvain-la-Neuve, Belgium, has established itself as a prominent developer, manufacturer, and provider of cutting-edge medical devices and software solutions for cancer treatment. The company operates through two primary segments: Proton Therapy and Other Accelerators, and Dosimetry. The Proton Therapy and Other Accelerators segment is dedicated to the development, fabrication, and servicing of advanced medical and industrial particle accelerators, including comprehensive proton therapy systems. These systems offer turnkey solutions for cancer treatment utilizing highly precise proton beams, representing a significant advancement over traditional radiation therapies. Additionally, this segment produces a range of cyclotrons essential for the production of positron emission tomography (PET) or SPECT radioisotopes, crucial for diagnostic imaging, alongside industrial accelerators used for sterilization and ionization processes across various industries. The Dosimetry segment focuses on delivering specialized solutions and services designed to enhance efficiency and minimize errors in radiation therapy, as well as ensuring quality assurance and calibration procedures in medical imaging. This commitment to precision and safety is vital in the oncology field. Ion Beam Applications S.A. extends its reach across Belgium, the United States, and international markets, demonstrating a global footprint in the healthcare sector. The company actively engages in strategic research and development, notably through a partnership with SCK CEN, the Belgian nuclear research center, aimed at enabling the production of Actinium-225 (225Ac), a novel radioisotope with significant potential for targeted cancer therapies. Furthermore, an agreement with the University of Pennsylvania underscores its dedication to advancing radiation oncology through research into ConformalFLASH, a promising ultra-high dose rate radiation delivery technique.

What Products and Services Does IOBCF Offer?

• Develop, manufacture, and service proton therapy systems for advanced cancer treatment.
• Provide turnkey solutions for cancer therapy using precise proton beams.
• Produce cyclotrons for the creation of positron emission tomography (PET) and SPECT radioisotopes, used in diagnostics.
• Manufacture industrial accelerators for sterilization and ionization processes across various industries.
• Offer dosimetry solutions and services to enhance efficiency and minimize errors in radiation therapy.
• Provide quality assurance and calibration procedures for medical imaging.
• Engage in strategic R&D partnerships for novel radioisotope production (Actinium-225) for targeted cancer therapies.
• Collaborate on advanced research in ConformalFLASH, an ultra-high dose rate radiation delivery technique.

How Does IOBCF Make Money?

• Sales and installation of proton therapy systems and industrial accelerators, often as comprehensive turnkey solutions.
• Recurring revenue from servicing, maintenance, and upgrades of installed particle accelerators and dosimetry equipment.
• Sales of cyclotrons for radioisotope production to medical and research facilities.
• Provision of dosimetry solutions and services for quality assurance and calibration in radiation therapy and medical imaging.
• Potential future revenue streams from the commercialization of novel radioisotopes and advanced radiation technologies developed through R&D partnerships.

What Industry Does IOBCF Operate In?

Ion Beam Applications S.A. operates within the Medical Devices industry, a critical segment of the broader Healthcare sector, specifically targeting advanced cancer treatment. The industry is characterized by continuous innovation, stringent regulatory requirements, and a growing global demand for more effective and less invasive therapies. IOBCF's focus on proton therapy systems places it in a specialized, high-growth niche within radiation oncology, where proton therapy is increasingly recognized for its precision in sparing healthy tissue. The dosimetry segment addresses the universal need for accuracy and quality assurance in all forms of radiation therapy and medical imaging, a market driven by patient safety and clinical efficacy standards. The competitive landscape includes other manufacturers of radiation therapy equipment and dosimetry solutions, but IOBCF differentiates itself through its comprehensive turnkey proton therapy offerings and pioneering R&D in novel radioisotopes and advanced radiation techniques, positioning it as a key player in the evolution of cancer care.

Who Are IOBCF's Key Customers?

• Hospitals and cancer treatment centers globally seeking advanced radiation therapy solutions.
• Research institutions and pharmaceutical companies requiring cyclotrons for radioisotope production.
• Industrial clients needing accelerators for sterilization, material modification, or environmental applications.
• Medical physics departments and radiation oncology clinics utilizing dosimetry equipment for quality control.
• Government and private entities investing in cutting-edge cancer treatment infrastructure.

Ion Beam Applications S.A. (IOBCF) Valuation Context

Valued at $545M, IOBCF is classified as a small-cap stock. Relative to its peer group, IOBCF's quantitative score of 51/100 is below the peer average of 75/100.

IOBCF Revenue & Earnings Trend

In Q4 2025, IOBCF generated $315.2M in top-line revenue, marking a sequential increase of 3.4%. The company recorded net income of $15.2M, with diluted EPS of $0.52. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, IOBCF averaged $0.19 in diluted EPS.

Company Profile

Ion Beam Applications S.A. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Louvain-la-Neuve, BE. The company is led by CEO Olivier Legrain. IOBCF has traded publicly since 2001.

Return on equity for Ion Beam Applications S.A. stands at 10.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.8%, showing how much profit it generates from its asset base. IOBCF trades at a trailing price-to-earnings ratio of 40.33, above the Healthcare sector average of ~23x. Its free cash flow yield is -6.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.99 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.

Ion Beam Applications S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.46 places it in the grey zone, a middle ground that warrants monitoring.

Wall Street analysts project Ion Beam Applications S.A. revenue of about $620.7M for fiscal 2026, with EPS near $0.74. The estimate reflects 4 contributing analysts.

IOBCF Financials

IOBCF Latest News

No recent news available for IOBCF.

IOBCF Analyst Consensus

IOBCF MoonshotScore

What Investors Ask About Ion Beam Applications S.A. (IOBCF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources